QUVIVIQ (daridorexant)

Self-Administration – oral

Diagnosis considered for coverage:
  • Indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Coverage Criteria:

For diagnosis of insomnia:

  • Dose does not exceed FDA label maximum dose of 50 mg per day; AND
  • Diagnosis of insomnia; AND
  • Potential factors contributing to sleep disturbances have been addressed (e.g., education on sleep hygiene and sleep environment issues, medications, physical or psychiatric disorder); AND
  • One of the following:
    • For patients < 65 years old:
        •  
      • Has tried and failed at least two preferred medications (e.g., eszopiclone, zaleplon, zolpidem/zolpidem ER, triazolam, temazepam, generic ramelteon) as confirmed by medical record documentation and/or prescription claims history; AND
      • Has tried and failed Dayvigo as confirmed by medical record documentation and/or prescription claims history
    •  
    • For patients > 65 years old: 
        •  
      • Has tried and failed at least one preferred medication (e.g., generic ramelteon) as confirmed by medical record documentation and/or prescription claims history; AND
      • Has tried and failed Dayvigo as confirmed by medical record documentation and/or prescription claims history
Reauthorization Criteria:

For diagnosis of insomnia

  • Dose does not exceed FDA label maximum dose of 50 mg per day; AND
  • Documentation of positive clinical response to therapy (e.g., improvement in sleep onset from baseline, sleep maintenance from baseline, total sleep time from baseline)
Coverage Duration:
  • Initial: 1 year
  • Reauthorization: 1 year
Authorization is not covered for the following:

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Additional Information:
  • Dosing:
    • The recommended dosage is 25 mg to 50 mg once per night, taken orally within 30 minutes before going to bed, with at least 7 hours remaining prior to planned awakening
    • Hepatic impairment:
      • Moderate hepatic impairment: maximum recommended dosage is 25 mg no more than once per night
      • Severe hepatic impairment: not recommended
  • Contraindication:
    • Quviviq is contraindicated in patients with narcolepsy
  • Drug interactions:
    • Strong CYP3A4 inhibitors: avoid concomitant use
    • Moderate or strong CYP3A4 inducers: avoid concomitant use
Policy Updates:
  • 08/16/2022 – New policy approved by P&T.
References:
  • Quviviq Prescribing Information. Idorsia Pharmaceuticals US Inc. Radnor, PA. April 2022.
  • Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: An American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307-349. Available at https://jcsm.aasm.org/doi/10.5664/jcsm.6470. Accessed May 9, 2022.
  • UpToDate. Overview of the Treatment of Insomnia in Adults. Available at https://www.uptodate.com/contents/overview-of-the-treatment-of-insomnia-in-adults?search=insomnia&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1. Accessed May 9, 2022.
  • The 2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 00:1-21, 2019. Available at https://www.uclahealth.org/geriatrics/workfiles/education/clinical-skills/handouts/Education-Updated-Beers-List-2019.pdf. Accessed May 9, 2022.

Last review date: August 16, 2022

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone